Lot 24-4511
Ipamorelin + CJC no DAC · 10mg
Research applications
- GH pulsatility models
- Selective secretagogue pharmacology
- Bone density research
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular weight
711.86 g/mol
Purity
≥99.1%
Abbreviation
IPA
Storage
Lyophilized: −20 °C. Reconstituted: 2–8 °C, 21 days.
Reconstitution
Add 2 mL BAC water to a 5 mg vial → 2.5 mg/mL.
Ipamorelin + CJC no DAC
Selective ghrelin receptor agonist.
A pentapeptide selective growth-hormone secretagogue. Studied for its selectivity profile in GH-axis research without significant cortisol or prolactin elevation.
Configure
£58.00
Vial size
Lot 24-4511 · lot-matched COA included · cold-chain shipping
Qty
Research Overview
Ipamorelin + CJC-1295 No DAC is a pre-blended research compound combining two of the most studied growth hormone secretagogues in a single 3ml pen cartridge. Each compound operates through a distinct but complementary receptor pathway, making this pairing a subject of significant interest in GH-axis research.
Ipamorelin — Selective Ghrelin Receptor Agonist
Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor (GHS-R1a), stimulating GH release from the anterior pituitary. It is widely studied for its selectivity profile — research has demonstrated minimal impact on cortisol and ACTH release, absence of significant prolactin elevation in preclinical models, and clean GH pulse stimulation without the appetite-stimulating effects associated with broader ghrelin mimetics such as GHRP-6.
CJC-1295 No DAC — GHRH Analogue
CJC-1295 (without DAC) is a 30-amino-acid synthetic analogue of growth-hormone-releasing hormone. The absence of the Drug Affinity Complex modification results in a shorter half-life suited to pulsatile release studies. Research has examined its binding affinity at GHRH receptors on pituitary somatotrophs and its ability to stimulate GH in a pulsatile pattern consistent with physiological secretion.
Synergistic Dual-Pathway Stimulation
The primary research interest in this combination lies in the simultaneous activation of two distinct GH-stimulating pathways. Studies have investigated the synergistic amplification of GH pulse amplitude compared to either compound alone, the interaction between ghrelin receptor signalling and GHRH receptor signalling in somatotroph cells, and the effect of dual-pathway stimulation on downstream IGF-1 dynamics in preclinical models.
For laboratory research use only. Not intended for human or animal consumption.